Skip to content

Study · Observational study · n = 20 · 1997

4 results

Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy.

Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, Craen M, Dooms L, Malvaux P, Kanen F, Bourguignon JP

Acta paediatrica (Oslo, Norway : 1992)1 Aug 1997Cited by 56 (Europe PMC)

PMID9307158 (opens in a new tab)DOI10.1111/j.1651-2227.1997.tb08602.x (opens in a new tab)PepBankPUB-09307158
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, loneliness tended to decrease during triptorelin treatment and increase without treatment.

    In plain wordsIn girls with early puberty, loneliness tended to decrease during triptorelin treatment and increase without treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseLoneliness
    Study

    n = 20

    Comparator
    Untreated girls
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Feelings of loneliness and exemplary behavior were observed and tended to decrease in the treated patients and to increase in the untreated patients.
    1 context sentence
    Summary · context
    The aim of the present study was to evaluate the behavioral and affective characteristics and the changes in psychosocial functioning resulting from precocious puberty in 15 girls with central precocious puberty treated for 2 y using the GnRH agonist long-acting triptorelin, and in 5 untreated girls.
  2. 02HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, exemplary behavior tended to decrease during triptorelin treatment and increase without treatment.

    In plain wordsIn girls with early puberty, exemplary behavior tended to decrease during triptorelin treatment and increase without treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseExemplary behavior
    Study

    n = 20

    Comparator
    Untreated girls
    Outcome group
    Locomotor and behavioral activity · Mental health and mood
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Feelings of loneliness and exemplary behavior were observed and tended to decrease in the treated patients and to increase in the untreated patients.
    1 context sentence
    Summary · context
    The aim of the present study was to evaluate the behavioral and affective characteristics and the changes in psychosocial functioning resulting from precocious puberty in 15 girls with central precocious puberty treated for 2 y using the GnRH agonist long-acting triptorelin, and in 5 untreated girls.
  3. 03HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, breast development regressed to minimal or absent levels in 5/15 during triptorelin therapy.

    In plain wordsIn girls with early puberty, breast development became minimal or absent in 5/15 during triptorelin therapy.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseBreast regression
    Study

    n = 15

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    During therapy, breast regression to minimal or absent development occurred in 5/15 treated patients, who then no longer felt embarrassed about pubertal development in contrast to the other patients.
    1 context sentence
    Summary · context
    The aim of the present study was to evaluate the behavioral and affective characteristics and the changes in psychosocial functioning resulting from precocious puberty in 15 girls with central precocious puberty treated for 2 y using the GnRH agonist long-acting triptorelin, and in 5 untreated girls.

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome

    In girls with central precocious puberty, those whose breast development regressed to minimal or absent levels during triptorelin therapy no longer felt embarrassed about pubertal development, in contrast to the other patients.

    In plain wordsIn girls with early puberty, those whose breasts regressed during triptorelin therapy no longer felt embarrassed, unlike the other patients.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseEmbarrassment about puberty
    Study

    n = 5

    Comparator
    Other patients
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    During therapy, breast regression to minimal or absent development occurred in 5/15 treated patients, who then no longer felt embarrassed about pubertal development in contrast to the other patients.
    1 context sentence
    Summary · context
    The aim of the present study was to evaluate the behavioral and affective characteristics and the changes in psychosocial functioning resulting from precocious puberty in 15 girls with central precocious puberty treated for 2 y using the GnRH agonist long-acting triptorelin, and in 5 untreated girls.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.